Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA
- PMID: 15208597
- DOI: 10.1016/j.jaci.2004.03.003
Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA
Abstract
Background: In animal models administration of immunostimulatory DNA sequences preferentially elicits T(H)1-dominated (type 1-dominated) immunity and can inhibit developing or ongoing T(H)2 (type 2) responses.
Objective: Our objective was to investigate this phenomenon in humans.
Methods: In a randomized, third party-blinded, placebo-controlled, proof-of-concept study conducted entirely in the winter in 19 adults with ragweed allergy, we administered 6 subcutaneous injections of purified Amb a 1 linked to the 22-base-long immunostimulatory phosphorothioate oligodeoxyribonucleotide 1018 (Amb a 1-immunostimulatory DNA sequence conjugate [AIC]). Before the course of AIC or placebo injections and 2 and 16 weeks afterward, we measured recall responses to ragweed, streptokinase, and PHA in short-term primary culture of fresh PBMCs after restimulation with antigen. We quantified regulatory cytokine and chemokine responses characteristic of T(H)2 immunity (IL-5, IL-13, CCL17 [TARC], and CCL22 [MDC]), and T(H)1 immunity (IFN-gamma, CXCL9 [Mig], and CXCL10 [IP-10]), as well as IL-10, a cytokine sometimes linked to regulatory T-cell populations.
Results: We demonstrated for the first time that human systemic in vivo ragweed-specific T(H)2 responses were selectively redirected toward T(H)1 responses, with significant increases in IFN-gamma, CXCL9, and CXCL10 and significant decreases in IL-5, CCL17, and CCL22 found at 2 and 16 weeks after the sixth injection. Cytokine and chemokine responses to the unrelated bacterial antigen streptokinase and the global capacity to mount immune responses on polyclonal activation with PHA did not change. No clinically significant systemic or local allergic reactions were associated with AIC or placebo injections.
Conclusions: AIC, injected in concentrations that were approximately 40-fold lower than those used in most murine studies published to date, led to a prolonged shift from T(H)2 immunity toward T(H)1 immunity and appeared to be safe. This novel approach has the potential for immune redirection in human immediate hypersensitivity diseases.
Similar articles
-
Local induction of a specific Th1 immune response by allergen linked immunostimulatory DNA in the nasal explants of ragweed-allergic subjects.Allergol Int. 2009 Dec;58(4):565-72. doi: 10.2332/allergolint.09-OA-0108. Epub 2009 Sep 25. Allergol Int. 2009. PMID: 19776676
-
Progress in the development of new methods of immunotherapy: potential application of immunostimulatory DNA-conjugated to allergens for treatment of allergic respiratory conditions.Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M. 2003;(94):304-12; discussion 312-3. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M. 2003. PMID: 15119051 Review.
-
Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response.J Allergy Clin Immunol. 2004 Feb;113(2):235-41. doi: 10.1016/j.jaci.2003.11.001. J Allergy Clin Immunol. 2004. PMID: 14767435 Clinical Trial.
-
Immunostimulatory sequence DNA linked to the Amb a 1 allergen promotes T(H)1 cytokine expression while downregulating T(H)2 cytokine expression in PBMCs from human patients with ragweed allergy.J Allergy Clin Immunol. 2001 Aug;108(2):191-7. doi: 10.1067/mai.2001.116984. J Allergy Clin Immunol. 2001. PMID: 11496233
-
[DNA vaccines against allergy].Nihon Rinsho. 2000 Jun;58(6):1307-14. Nihon Rinsho. 2000. PMID: 10879058 Review. Japanese.
Cited by
-
IL2RB Is a Prognostic Biomarker Associated with Immune Infiltrates in Pan-Cancer.J Oncol. 2022 Apr 29;2022:2043880. doi: 10.1155/2022/2043880. eCollection 2022. J Oncol. 2022. Retraction in: J Oncol. 2023 Nov 1;2023:9807856. doi: 10.1155/2023/9807856. PMID: 35528245 Free PMC article. Retracted.
-
Formulations for Allergen Immunotherapy in Human and Veterinary Patients: New Candidates on the Horizon.Front Immunol. 2020 Aug 4;11:1697. doi: 10.3389/fimmu.2020.01697. eCollection 2020. Front Immunol. 2020. PMID: 32849594 Free PMC article. Review.
-
Novel Toll-Like Receptor 9 Agonist Derived from Cryptococcus neoformans Attenuates Allergic Inflammation Leading to Asthma Onset in Mice.Int Arch Allergy Immunol. 2020;181(9):651-664. doi: 10.1159/000508535. Epub 2020 Jun 25. Int Arch Allergy Immunol. 2020. PMID: 32585675 Free PMC article.
-
DNA and mRNA vaccination against allergies.Pediatr Allergy Immunol. 2018 Nov;29(7):679-688. doi: 10.1111/pai.12964. Epub 2018 Sep 20. Pediatr Allergy Immunol. 2018. PMID: 30063806 Free PMC article. Review.
-
Current Status of Potential Therapies for IgE-Mediated Food Allergy.Curr Allergy Asthma Rep. 2018 Feb 22;18(3):18. doi: 10.1007/s11882-018-0772-z. Curr Allergy Asthma Rep. 2018. PMID: 29470658 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials